secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001005286-25-000106
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M
--------------------------------------------------------------------------------

- Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.
- FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.
- Signed nine new customer programs in FY2025; post-quarter added GLP-1 obesity therapy and Phase 2 dermatology programs.
- Transition period (May-Dec 2025) guidance: revenue $74-76M; adj. EBITDA $12-14M; net loss $19.8-17.8M.
- Moving fiscal year to calendar year-end Dec 31, 2025; new ERP system planned for Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/0001005286-25-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/lndc-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001005286-25-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer